These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32766257)

  • 1. Utility of [
    Sa R; Liu D; Zhao H; Hou S; Lin Q; Guan F
    Front Med (Lausanne); 2020; 7():281. PubMed ID: 32766257
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical value of baseline
    Reyes Marlés RH; Navarro Fernández JL; Puertas García-Sandoval JP; Santonja Medina F; Mohamed Salem L; Frutos Esteban L; Contreras Gutiérrez JF; Castellón Sánchez MI; Ruiz Merino G; Claver Valderas MA
    Eur J Hybrid Imaging; 2021 Sep; 5(1):16. PubMed ID: 34476632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
    Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
    Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Jiang CZ; Zheng K; Zhang YY; Yang J; Ye H; Peng X
    Front Oncol; 2024; 14():1278464. PubMed ID: 38947896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative
    Lim WS; Oh JS; Roh JL; Kim JS; Kim SJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Feb; 77():98-104. PubMed ID: 29362133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Parameters of
    Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
    Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volumetric parameters on
    Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
    BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evaluation of Preoperative
    Vural Topuz Ö; Aksu A; Erinç SR; Tokgözoğlu N; Tamam MÖ
    Mol Imaging Radionucl Ther; 2022 Feb; 31(1):16-22. PubMed ID: 35114747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.
    Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH
    J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of
    Zheng F; Wanjun X; Shuaishuai W; Tong W; Lue Z
    Med Int (Lond); 2021; 1(5):23. PubMed ID: 36698530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.
    Tanaka A; Sekine T; Ter Voert EEGW; Zeimpekis KG; Delso G; de Galiza Barbosa F; Warnock G; Kumita SI; Veit Haibach P; Huellner M
    Front Med (Lausanne); 2022; 9():796085. PubMed ID: 35308500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.